Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting

May 14, 2018

STAMFORD, Conn., May 14, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced presentations at the International Investigative Dermatology (IID) 2018 Meeting, to be held May 16-19, 2018 in Orlando.

Details for the presentations are as follows:

Oral and Poster Presentation:

Title:	*"Antipruritic effect of the novel kappa opioid receptor agonist CR845"*
Date / Time:	Saturday, May 19, 2018, 3:15–5:45 p.m. EDT
Presenter:	Robert H. Spencer, Senior Director, Research & Development, Cara Therapeutics

Poster Presentations:

Title:	*"Measurement of pruritus associated with chronic-kidney disease in hemodialysis patients: a qualitative study of two patient-reporte*
Date / Time:	Thursday, May 17, 2018, 11:45 a.m.–1:45 p.m. EDT
Presenter:	Catherine Munera, Head of Biometrics, Cara Therapeutics

Title:	*"Psychometric validation and meaningful change threshold of the worst itching intensity numerical rating scale for use in hemodialy*
Date / Time:	Saturday, May 19, 2018, 11:45 a.m.–1:45 p.m. EDT
Presenter:	Catherine Munera, Head of Biometrics, Cara Therapeutics

For information about IID 2018, visit https://iid2018.org.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Additionally, CR845/difelikefalin has demonstrated efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product, and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
michael@sternir.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

Primary Logo

Source: Cara Therapeutics, Inc.